SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in SCWorx Corporation of Class Action Lawsuit and Upcoming Deadline - WORX

NEW YORK, June 24, 2020 /PRNewswire/ --A Pomerantz LLP announces that a class action lawsuit has been filed against SCWorx Corporation ("SCWorx" or the "Company") (NASDAQ: WORX) and certain of its officers.A  The class action, filed in United States District Court for the Southern District of New York, and indexed under 20-cv-04072, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired SCWorx securities between April 13, 2020, and April 17, 2020, inclusive (the "Class Period").A  Plaintiff pursues claims against the Defendants under the Securities Exchange Act of 1934 (the "Exchange Act").If you are a shareholder who purchased SCWorx securities during the class period, you have until June 29, 2020, to ask the Court to appoint you as Lead Plaintiff for the class.A  A copy of the Complaint can be obtained at A  To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.comA or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.A  [Click here for information about joining the class action]SCWorx provides data content and services related to the repair, normalization, and interoperability of information for healthcare providers.The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about SCWorx's business, operations, and prospects.A  Specifically, Defendants failed to disclose to investors that:A (i) SCWorx's supplier for COVID-19 tests had previously misrepresented its operations; (ii) SCWorx's buyer was a small company that was unlikely to adequately support the purported volume of orders for COVID-19 tests; (iii) as a result, the Company's purchase order for COVID-19 tests had been overstated or entirely fabricated; and (iv) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Октябрь 2022    »